<DOC>
	<DOC>NCT00556140</DOC>
	<brief_summary>The purpose of the study is to assess the safety and effectiveness of the combination of aripiprazole (Abilify) and selective serotonin reuptake inhibitors (SSRIs) in subjects with psychotic major depression.</brief_summary>
	<brief_title>The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Serotonin</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>1. Men and women aged 1880 years, inclusive. 2. Drugfree outpatients or inpatients meeting DSMIV criteria for major depression with psychotic features. 3. Inpatients who undergo a 57 day washout period of their medication while concurrently beginning one of the approved SSRI's and abilify. 4. HAMD24 score &gt; 16. 1. Pregnant women and women of child bearing potential not using a medically accepted means of contraception (oral contraceptives are allowed). 2. Women who are breastfeeding. 3. Patients meeting DSMIV criteria for major depression without psychotic features, or psychosis without major depression at the screen visit. 4. Patients with serious suicidal risk. 5. Patients with a history of seizure disorder; unstable physical disorders (cardiovascular, hepatic, renal, respiratory, endocrine, neurologic, or hematologic); or any physical disorder judged to significantly affect central nervous system function. 6. Patients meeting criteria for the following DSMIV diagnoses: organic mental disorders; substance use disorders, including alcohol, active within the last 6 months; bipolar disorder; schizoaffective disorder; or antisocial personality disorder. 7. Patients who are currently taking an antidepressant, antipsychotic, or mood stabilizing drug and who are responding to one or all of these medications. If patients are not responding to these medications, they may go through a washout period of at least one week under the supervision of a study doctor before entering into this study. 8. Patients who are not able to read and understand the consent form, or who are not capable of understanding or giving informed consent to the procedures of the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>